Clinical Trials Logo

Metastatic Cancer clinical trials

View clinical trials related to Metastatic Cancer.

Filter by:

NCT ID: NCT00005616 Completed - Colorectal Cancer Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Start date: September 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have colorectal cancer.

NCT ID: NCT00005610 Completed - Metastatic Cancer Clinical Trials

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Start date: September 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Colony-stimulating factors, such as sargramostim, may help the body's immune system to kill cancer cells. Giving sargramostim in different ways may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of sargramostim given as a breathing treatment for treating patients who have melanoma that is metastatic to the lung.

NCT ID: NCT00005030 Withdrawn - Colorectal Cancer Clinical Trials

SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver

Start date: September 29, 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to compare the effectiveness of different doses of SCH 66336 before surgery in treating patients who have colorectal cancer that has metastasized to the liver.

NCT ID: NCT00004930 Completed - Lung Cancer Clinical Trials

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases

Start date: July 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have primary lung cancer or lung metastases.

NCT ID: NCT00004604 Completed - Breast Cancer Clinical Trials

Biological Therapy in Treating Patients With Metastatic Cancer

Start date: February 1997
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment.

NCT ID: NCT00004142 Completed - Colorectal Cancer Clinical Trials

Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Start date: August 5, 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy delivered directly into the blood vessels of the liver may prevent new tumors from growing. Combining these therapies may be an effective treatment for colorectal cancer that has spread to the liver. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation followed by chemotherapy delivered directly into the blood vessels of the liver in treating patients who have colorectal cancer that has spread to the liver.

NCT ID: NCT00004136 Completed - Metastatic Cancer Clinical Trials

Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

Start date: March 9, 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Heating tumors to several degrees above body temperature may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of heat therapy in treating patients who have unresectable primary or metastatic liver cancer.

NCT ID: NCT00003941 Completed - Metastatic Cancer Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer

Start date: April 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy and kill more cancer cells. It is not yet known whether chemotherapy and peripheral stem cell transplant is more effective than chemotherapy alone. PURPOSE: This randomized phase III trial is studying how well combination chemotherapy works when given with peripheral stem cell transplant and how it compares with combination chemotherapy alone in treating men with previously untreated germ cell cancer.

NCT ID: NCT00003911 Terminated - Metastatic Cancer Clinical Trials

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

Start date: July 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic radiosurgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy followed by stereotactic radiosurgery in treating patients who have brain metastases from malignant melanoma.

NCT ID: NCT00003907 Completed - Metastatic Cancer Clinical Trials

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Start date: December 15, 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be surgically removed.